If you've been shopping for GLP-1 weight loss treatment, you've probably encountered two very different price points: brand-name Wegovy at over $1,200 per month, and compounded semaglutide starting as low as $179. Both contain the same active ingredient. So what's actually different?
Let's take an honest look at the similarities, the differences, and everything you should consider before choosing.
The Short Answer
Compounded semaglutide and brand Wegovy contain the same active ingredient: semaglutide. The differences lie in the manufacturing source, the regulatory pathway, and most significantly, the price.
What Is Wegovy?
Wegovy is a brand-name medication manufactured by Novo Nordisk. It was FDA-approved in 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It's been studied extensively in the STEP clinical trial program (over 4,000 participants).
What Is Compounded Semaglutide?
Compounded semaglutide is semaglutide, the same molecule, prepared by a licensed compounding pharmacy. Under FDA regulations, compounding pharmacies can legally produce medications when the brand-name version is in shortage.
Key Differences
Is Compounded Semaglutide Legal?
Yes. Under FDA regulations, 503B outsourcing facilities are permitted to compound medications during shortages. These facilities must:
Safety Considerations
Safety depends on the source. What to look for:
At Majesta Health, we meet all of these standards.
Which One Should You Choose?
Choose brand Wegovy if: Your insurance covers it with a reasonable co-pay, or cost isn't a concern.
Choose compounded semaglutide if: You don't have insurance coverage, your co-pay is still expensive, or you want the same active ingredient at a more affordable price.
The Majesta Health Difference
Compounded semaglutide starts at $179 for the first month and $299/month after, everything included: medication, board-certified physician consultations, ongoing monitoring, and free shipping.
Ready to find out if semaglutide is right for you? Start with our 2-minute medical assessment.
Related guides
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider. Individual results may vary. Compounded semaglutide has not been FDA-approved for safety and efficacy; please discuss the risks and benefits with your prescribing physician.
<!-- related-2026-injected -->
Related 2026 guides
Frequently Asked Questions
What is the difference between compounded semaglutide and Wegovy?
Both use semaglutide as the active ingredient. Wegovy is the FDA-approved finished drug manufactured by Novo Nordisk in a specific commercial formulation, dosed up to 2.4 mg per week and FDA-approved for chronic weight management. Compounded semaglutide is prepared by a state-licensed compounding pharmacy under a US physician prescription for an individual patient and may be formulated as injection or sublingual tablet. The active pharmaceutical ingredient is FDA-registered. Compounded medications are not FDA-approved as final products.
How much does compounded semaglutide save vs Wegovy?
Wegovy lists around $1,349 a month at retail without insurance. Compounded semaglutide through a state-licensed telehealth provider typically runs $179 to $399 a month all-in, including physician consultation and shipping. Over a 12-month treatment course, that is roughly $14,000 to $16,000 less out of pocket. Patients with Wegovy insurance coverage may pay less than compounded, depending on copay structure.
Is compounded semaglutide safe compared to Wegovy?
Both rely on the same active ingredient. Safety on compounded semaglutide depends on physician oversight, pharmacy compliance with USP 795 and 797 sterile compounding standards, and patient monitoring. Wegovy safety is established through FDA-supervised clinical trials including STEP-1 through STEP-5 and SELECT. Compounded medications are not FDA-approved as final products, so the safety record is built on the FDA-registered active pharmaceutical ingredient plus the regulatory framework around the dispensing pharmacy rather than on brand-name finished-drug trials.
Why is compounded semaglutide cheaper than Wegovy?
Three structural reasons. First, compounding pharmacies have far lower fixed costs than brand-name pharmaceutical manufacturers, no separate FDA filings, marketing, sales reps, or patent-recovery pricing. Second, compounded semaglutide is dispensed directly through telehealth platforms without distributor markups. Third, the active pharmaceutical ingredient sourced for compounding is significantly cheaper per gram than the finished drug. The total result is a 70 to 90 percent reduction in monthly out-of-pocket cost for a comparable dose under physician supervision.
Will Wegovy or compounded semaglutide be available in 2026?
Wegovy remains FDA-approved and on the market in 2026, with supply largely stable after the 2022-2024 shortage period. Compounded semaglutide continues to be available through US-licensed compounding pharmacies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act for individualized patient prescriptions. The FDA removed semaglutide from the official shortage list in early 2025, which tightened compliance requirements for compounding pharmacies. State-licensed pharmacies with NABP accreditation and LegitScript certification continue to dispense within the regulatory framework.
All Majesta Health medical content is clinically reviewed before publication by US-licensed physicians affiliated with our clinical infrastructure partner, MD Integrations (MDI). Reviewers hold active state medical licenses, are board-certified in primary care or obesity medicine, and specialize in GLP-1 receptor agonist therapy for chronic weight management. MDI is LegitScript certified and SOC 2 Type II accredited.
- US-licensed physicians affiliated with our clinical partner MD Integrations (LegitScript certified, HIPAA, SOC 2 Type II, ISO certified)
- Board-certified in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across all 50 US states and DC through the MD Integrations Medical Services Organization
- Dispensing pharmacy partner: Belmar Pharma Solutions (LegitScript certified, NABP accredited, 503A and 503B compounding)